Francis, Jeffrey C. http://orcid.org/0000-0001-6646-5749
Capper, Amy
Rust, Alistair G.
Ferro, Klea
Ning, Jian
Yuan, Wei
de Bono, Johann
Pettitt, Stephen J. http://orcid.org/0000-0003-3313-3857
Swain, Amanda http://orcid.org/0000-0001-8666-1608
Funding for this research was provided by:
Prostate Cancer UK (PG13-019)
Article History
Received: 15 September 2023
Revised: 2 April 2024
Accepted: 5 April 2024
First Online: 23 April 2024
Competing interests
: JdB has served on advisory boards and received fees from companies including Amgen, AstraZeneca, Astellas, Bayer, Bioxcel Therapeutics, Daiichi, Genentech/Roche, GSK, Harpoon, ImCheck Therapeutics, Immunic, Janssen, Merck Serono, Metacurum, Merck Sharp & Dohme, Myricx, Oncternal, Pfizer, Sanofi Aventis. JdB is an employee of The Institute of Cancer Research, which have received funding or other support for his research work from AstraZeneca, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Orion, Sanofi Aventis, Taiho, and Pfizer. The ICR has a commercial interest in abiraterone and PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income). JdB was named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids. He has been the CI/PI of many industry sponsored clinical trials. JdB is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.